Skip to main content

Signature Dx to Use Affymetrix Chips for Cancer Test Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix and Signature Diagnostics today announced that they have inked an agreement under which Signature Dx has gained a worldwide license to use Affymetrix's microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer tests.

Potsdam, Germany-based Signature Dx intends to launch two microarray-based IVD tests by the fourth quarter of this year for colorectal cancer, the firms said. Signature will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.

Signature has been developing the tests, called Detector C and Predictor C. Detector C is a non-invasive, blood-based early detection test that the firm said has shown 90 percent sensitivity and 88 percent specificity for all four stages of colorectal cancer. Predictor C is a tissue test that predicts disease progression in stage II and III colorectal cancer patients and has been shown to identify half of all stage II/III patients with a high risk of disease progression.

"Our novel Detector C blood screening product together with Affymetrix's gene expression array technology brings CRC screening to a new level of accuracy and sensitivity," André Rosenthal, CEO of Signature Diagnostics, said in a statement.

Financial terms of the agreement were not disclosed.

The deal is part of Affy's 'Powered by Affymetrix's partnering program.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.